21.07.2011 • News

Abbott Laboratories Q2 Profit Surges 50%

Abbott Laboratories reported Wednesday a profit for the second quarter that surged 50% from last year, boosted largely by a significant tax benefit and sales growth. This was partially offset by higher operating costs, mainly for research and development.

Excluding items, ongoing earnings per share for the quarter grew 11% and topped analysts' expectations by a penny. The company also raised its ongoing earnings forecast for the full-year 2011, citing the strong performance to date.

The Abbott Park, Ill.-based drug maker reported net earnings of $1.94 billion or $1.23 per share for the second quarter, sharply higher than $1.29 billion or $0.83 per share in the prior-year quarter.

The results for the latest quarter primarily included a tax resolution benefit of $519 million or $0.33 per share, and $173 million or $0.11 per share charge related to acquisition.

 

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.